NADPH-P450 Reductase, rHuman - Citations

NADPH-P450 Reductase, rHuman - Citations

View additional product information for NADPH-P450 Reductase, rHuman - Citations (P2309)

Showing 2 product Citations

Citations & References
Abstract
Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
AuthorsTracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ,
JournalDrug Metab Dispos
PubMed ID11901091
'CYP2C9 wild-type protein has been shown to exhibit atypical kinetic profiles of metabolism that may affect in vitro-in vivo predictions made during the drug development process. Previous work suggests a substrate-dependent effect of polymorphic variants of CYP2C9 on the rate of metabolism; however, it is hypothesized that these active site ... More
2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor.
AuthorsHecht SS, Hochalter JB, Villalta PW, Murphy SE,
JournalProc Natl Acad Sci U S A
PubMed ID11050152
'Smokers or people undergoing nicotine replacement therapy excrete approximately 10% of the nicotine dose as 4-oxo-4-(3-pyridyl)butanoic acid (keto acid) and 4-hydroxy-4-(3-pyridyl)butanoic acid (hydroxy acid). Previously, these acids were thought to arise by secondary metabolism of the major nicotine metabolite cotinine, but our data did not support this mechanism. Therefore, we ... More